Evidence map›Paper›PMID 36229537›Full record

Trial reportHypertension research : official journal of the Japanese Society of Hypertension2023

Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus-results from the TRIUMPH randomised controlled trial.

Sonali R Gnanenthiran, Ruth Webster, Asita de Silva, Pallab K Maulik, Abdul Salam, Vanessa Selak, Rama K Guggilla, Aletta E Schutte, Anushka Patel, Anthony Rodgers and 1 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Optimizing antihypertensive therapy in patients with diabetes mellitus.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 5 countries.

Sonali R GnanenthiranThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Ruth WebsterThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Asita de SilvaClinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.
Pallab K MaulikThe George Institute for Global Health, Hyderabad, India.
Abdul SalamThe George Institute for Global Health, Hyderabad, India.
Vanessa SelakDepartment of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand.
Rama K GuggillaDepartment of Population Medicine and Lifestyle Diseases Prevention, Faculty of Medicine with the Division of Dentistry and Division of Medical Education in English, Medical University of Bialystok, Bialystok, Poland.
Aletta E SchutteThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Anushka PatelThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Anthony RodgersThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. arodgers@georgeinstitute.org.
TRIUMPH Study Group
National Hospital of Sri Lanka · LKColombo North Teaching Hospital · LKUNSW Sydney · AUUniversity of Sri Jayewardenepura · LKGeorge Institute for Global Health · INMedical University of Białystok · PLUniversity of Auckland · NZUniversity of Kelaniya · LK

Funding

Medical Research Council MR/S023224/1
6 · The paper itself

Abstract

We investigated whether diabetes mellitus (DM) affects the efficacy of a low-dose triple combination pill and usual care among people with mild-moderate hypertension. TRIUMPH (TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension) was a randomised controlled open-label trial of patients requiring initiation or escalation of antihypertensive therapy. Patients were randomised to a once-daily low-dose triple combination polypill (telmisartan-20mg/amlodipine-2.5 mg/chlorthalidone-12.5 mg) or usual care. This analysis compared BP reduction in people with and without DM, both in the intervention and control groups over 24-week follow-up. Predicted efficacy of prescribed therapy was calculated (estimation methods of Law et al.). The trial randomised 700 patients (56 ± 11 yrs, 31% DM). There was no difference in the number of drugs prescribed or predicted efficacy of therapy between people with DM and without DM. However, the observed BP reduction from baseline to week 24 was lower in those with DM compared to non-diabetics in both the triple pill (25/11 vs 31/15 mmHg, p ≤ 0.01) and usual care (17/7 vs 22/11 mmHg, p ≤ 0.01) groups, and these differences remained after multivariable adjustment. DM was a negative predictor of change in BP (β-coefficient -0.08, p = 0.02). In conclusion, patients with DM experienced reduced efficacy of BP lowering therapies as compared to patients without DM, irrespective of the type of BP lowering therapy received.

Indexed as

Diabetes MellitusHypertensionAmlodipineAntihypertensive AgentsBlood PressureChlorthalidoneDrug CombinationsHumansAmlodipineAntihypertensive AgentsChlorthalidoneDrug CombinationsBlood pressureDiabetesHypertensionPolypill

Identifiers

PMID36229537
OpenAlexW4306149934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.